Published in Transplantation on September 15, 1996
Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol (2003) 1.07
Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen. Pediatr Nephrol (2008) 1.07
Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J Clin Invest (1997) 0.90
A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol (2006) 0.89
Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol (2010) 0.86
Therapeutic drug monitoring of immunosuppressant drugs. Br J Clin Pharmacol (1999) 0.83
Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation. Clin J Am Soc Nephrol (2009) 0.78
Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid. Eur J Clin Pharmacol (2012) 0.78
The transplanted child: New immunosuppressive agents and the need for pharmacokinetic monitoring. Paediatr Child Health (2002) 0.76
Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy? Clin Exp Immunol (2016) 0.75
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant (2009) 3.43
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int (1993) 3.11
Tolerance versus immunosuppression: a perspective. Am J Transplant (2008) 2.71
Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28
Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant (2007) 2.25
De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant (2009) 2.24
FOXP3 expression in human kidney transplant biopsies is associated with rejection and time post transplant but not with favorable outcomes. Am J Transplant (2008) 1.94
A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant (2012) 1.93
The Mexican asthma cure. Systemic steroids for gullible gringos. Chest (1990) 1.69
Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant (2010) 1.65
NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant (2010) 1.62
The nature of biopsies with "borderline rejection" and prospects for eliminating this category. Am J Transplant (2011) 1.60
Ischemic acute tubular necrosis induces an extensive local cytokine response. Evidence for induction of interferon-gamma, transforming growth factor-beta 1, granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-10. Transplantation (1995) 1.59
The 'two, one, zero' decision: what to do with suboptimal deceased donor kidneys. Am J Transplant (2010) 1.58
Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant (2013) 1.57
The molecular phenotype of heart transplant biopsies: relationship to histopathological and clinical variables. Am J Transplant (2010) 1.54
Lies, damn lies, and statistics: the perils of the P value. Am J Transplant (2006) 1.50
The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transplant (2015) 1.48
Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant (2007) 1.44
The molecular phenotype of 6-week protocol biopsies from human renal allografts: reflections of prior injury but not future course. Am J Transplant (2010) 1.43
Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res (1999) 1.41
Renal failure after eating "magic" mushrooms. CMAJ (1992) 1.40
Immunosuppressive activity of cyclosporine metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance. Clin Chem (1990) 1.39
Interference of fetal hemoglobin and labile glycosylated hemoglobin with measurements of glycosylated hemoglobin. Clin Chem (1983) 1.39
Therapeutic monitoring of cyclosporine, FK-506, and rapamycin. Ther Drug Monit (1992) 1.39
Telomere shortening in kidneys with age. J Am Soc Nephrol (2000) 1.29
Delayed graft function in renal transplantation: etiology, management and long-term significance. J Urol (1996) 1.28
The regulation of expression of major histocompatibility complex products. Transplantation (1986) 1.27
Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant (2013) 1.25
Scoring total inflammation is superior to the current Banff inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts. Am J Transplant (2009) 1.21
Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches. Am J Transplant (2009) 1.19
Conservation of genes coding for proteins synthesized in human mitochondria. Somatic Cell Genet (1978) 1.19
Changes in Ia expression in mouse kidney during acute graft-vs-host disease. J Immunol (1984) 1.17
Canadian Consensus Meeting on cyclosporine monitoring: report of the consensus panel. Clin Chem (1990) 1.16
Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts. Am J Transplant (2013) 1.16
Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases. Am J Transplant (2011) 1.16
IFN regulatory factor-1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo. J Immunol (1997) 1.15
Microcirculation lesions alone are not reliable for identifying antibody-mediated rejection. Am J Transplant (2013) 1.13
The transcriptome of the implant biopsy identifies donor kidneys at increased risk of delayed graft function. Am J Transplant (2007) 1.13
The use of mycophenolate mofetil in transplant recipients. Immunopharmacology (2000) 1.13
Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema. Transplantation (1996) 1.12
Comparing microarray versus RT-PCR assessment of renal allograft biopsies: similar performance despite different dynamic ranges. Am J Transplant (2008) 1.10
SWOT analysis of Banff: strengths, weaknesses, opportunities and threats of the international Banff consensus process and classification system for renal allograft pathology. Am J Transplant (2007) 1.10
Increased major histocompatibility complex antigen expression in unilateral ischemic acute tubular necrosis in the mouse. Transplantation (1990) 1.09
Interferon-gamma and donor MHC class I control alternative macrophage activation and activin expression in rejecting kidney allografts: a shift in the Th1-Th2 paradigm. Am J Transplant (2008) 1.06
Ethylene glycol quantification: avoid propylene glycol as an internal standard. Clin Chem (1990) 1.06
Cell senescence and its implications for nephrology. J Am Soc Nephrol (2001) 1.06
Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant (2012) 1.06
Continued function of pancreatic islets after transplantation in type I diabetes. Lancet (1989) 1.05
Effects of donor age and cell senescence on kidney allograft survival. Am J Transplant (2009) 1.03
Changes in the transcriptome in allograft rejection: IFN-gamma-induced transcripts in mouse kidney allografts. Am J Transplant (2006) 1.03
Molecular correlates of scarring in kidney transplants: the emergence of mast cell transcripts. Am J Transplant (2008) 1.02
Inhibition of MHC product induction may contribute to the immunosuppressive action of ciclosporin. Prog Allergy (1986) 1.01
The transcriptome of human cytotoxic T cells: measuring the burden of CTL-associated transcripts in human kidney transplants. Am J Transplant (2008) 1.01
Does iron deficiency raise the seizure threshold? J Child Neurol (1995) 1.00
Cluster analysis of lesions in nonselected kidney transplant biopsies: microcirculation changes, tubulointerstitial inflammation and scarring. Am J Transplant (2010) 0.98
Tacrolimus metabolite cross-reactivity in different tacrolimus assays. Clin Biochem (1998) 0.98
Accelerated expression of senescence associated cell cycle inhibitor p16INK4A in kidneys with glomerular disease. Kidney Int (2006) 0.97
Transcriptome analysis reveals heterogeneity in the injury response of kidney transplants. Am J Transplant (2007) 0.96
Quantification of nonenzymically glycated albumin and total serum protein by affinity chromatography. Clin Chem (1984) 0.96
The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant (2014) 0.96
Protocol biopsies in renal transplantation: insights into patient management and pathogenesis. Am J Transplant (2007) 0.96
Time dependency of factors affecting renal allograft survival. J Am Soc Nephrol (2000) 0.95
Expression of B cell and immunoglobulin transcripts is a feature of inflammation in late allografts. Am J Transplant (2008) 0.95
Molecular landscape of T cell-mediated rejection in human kidney transplants: prominence of CTLA4 and PD ligands. Am J Transplant (2014) 0.94
Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Kidney Dis (1999) 0.94
Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clin Biochem (1998) 0.93
Cyclosporine metabolite cross-reactivity in different cyclosporine assays. Clin Biochem (1998) 0.93
Early loss of renal transcripts in kidney allografts: relationship to the development of histologic lesions and alloimmune effector mechanisms. Am J Transplant (2007) 0.93
Multiple low dose streptozotocin induces systemic MHC expression in mice by triggering T cells to release IFN-gamma. J Immunol (1989) 0.92
Loss of solute carriers in T cell-mediated rejection in mouse and human kidneys: an active epithelial injury-repair response. Am J Transplant (2010) 0.91
The transcriptome of human cytotoxic T cells: similarities and disparities among allostimulated CD4(+) CTL, CD8(+) CTL and NK cells. Am J Transplant (2008) 0.91
The early course of kidney allograft rejection: defining the time when rejection begins. Am J Transplant (2009) 0.91
Defining the canonical form of T-cell-mediated rejection in human kidney transplants. Am J Transplant (2010) 0.90
Identification of a calcium-inducible, cyclosporine sensitive element in the IFN-gamma promoter that is a potential NFAT binding site. Transplantation (1996) 0.90
Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J Clin Invest (1997) 0.90
The puzzling role of CXCR3 and its ligands in organ allograft rejection. Am J Transplant (2008) 0.89
Regulation of IFN-gamma and tumor necrosis factor-alpha expression in vivo. Effects of cycloheximide and cyclosporine in normal and lipopolysaccharide-treated mice. J Immunol (1993) 0.89
Regulation of MHC expression in vivo. Bacterial lipopolysaccharide induces class I and II MHC products in mouse tissues by a T cell-independent, cyclosporine-sensitive mechanism. J Immunol (1988) 0.89
Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am J Transplant (2001) 0.88
Peritubular capillaries in chronic renal allograft rejection: a quantitative ultrastructural study. Hum Pathol (2000) 0.87
Ly-6 in kidney is widely expressed on tubular epithelium and vascular endothelium and is up-regulated by interferon gamma. J Am Soc Nephrol (1993) 0.87
The unique role of interferon-gamma in the regulation of MHC expression on arterial endothelium. Transplantation (1996) 0.87
Pharmacokinetics and metabolism of sirolimus. Ther Drug Monit (2000) 0.87
Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation (2000) 0.87
Interferon-gamma levels in peritoneal dialysis effluents: relation to peritonitis. Kidney Int (1994) 0.86
Disturbed MHC regulation in the IFN-gamma knockout mouse. Evidence for three states of MHC expression with distinct roles for IFN-gamma. J Immunol (1995) 0.86
Regulation of IFN-gamma expression in vivo. IFN-gamma up-regulates expression of its mRNA in normal and lipopolysaccharide-stimulated mice. J Immunol (1993) 0.86
Evaluation of the CLINITEK ATLAS for routine macroscopic urinalysis. Clin Biochem (1996) 0.85
Effect of recombinant human insulin-like growth factor-1 on the inflammatory response to acute renal injury. J Am Soc Nephrol (1996) 0.85
Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther (1999) 0.85
Therapeutic monitoring of rapamycin: a new immunosuppressive drug. Ther Drug Monit (1993) 0.85
The islet transplant experiment: time for a reassessment. Am J Transplant (2007) 0.84
Public awareness of organ donation. CMAJ (1988) 0.84
Graft-vs-host reactions induce H-2 class II gene transcription in host kidney cells. Immunogenetics (1984) 0.84